Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech…
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.
Independent research firm Argus has reviews of three of health care picks from its own Focus List in which it still sees significant upside ahead.
24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a single tweet did to them last week.
The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
According to Fitch Ratings, biosimilars are beginning to take share from their reference biologics. This is seen in the debut of the first biosimilar drug in the United States.
Chris Lange Amgen and Xencor have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
Chris Lange The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased across the board for this settlement date.
Tuesday’s top analyst upgrades, downgrades and initiations include Amgen, Dow Chemical, Fitbit, Office Depot, SanDisk, Wells Fargo and Yum! Brands.
Amgen has the potential to disrupt the market for cholesterol drugs with the newest addition to its drug portfolio.
Chris Lange The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks.
The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech stocks backed off for this period.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
According to Argus, second-quarter earnings, along with a strong pipeline and general outlook, have positioned Amgen to take the market by storm.
Chris Lange 
